Featured Research

from universities, journals, and other organizations

Artificial Il-4 Receptor Could Stop Allergies, Help People With Allergic Asthma

Date:
May 11, 1998
Source:
National Jewish Medical And Research Center
Summary:
Researchers at National Jewish Medical and Research Center are performing clinical trials and basic science research on laboratory-made IL-4 receptors, which have been shown to successfully bind to IL-4 in humans.

DENVER--Researchers at National Jewish Medical and Research Center are performing clinical trials and basic science research on laboratory-made IL-4 receptors, which have been shown to successfully bind to IL-4 in humans. National Jewish researchers are currently testing an inhaled form of the IL-4 receptor.

When an allergen enters the body it stimulates production of the gene IL-4. When IL-4 attaches to an IL-4 receptor, found on cells in the body, this contact produces IgE. IgE causes the immune system to respond in the form of a runny nose, watery eyes and other symptoms. In many people with asthma, the IL-4 receptor is highly sensitive, which causes allergic asthma.

"This goes at the source of allergies. We're not treating symptoms, we're eliminating disease," said Larry Borish, M.D., a physician researcher in the National Jewish Department of Medicine.

The inhaled IL-4 receptor doesn't stop the body's production of IL-4. Instead the inhaled IL-4 receptor "soaks up" the body's available IL-4 by chemically binding to it before it reaches and activates the IL-4 receptor on the surface of the cell. "It is like a sponge," Dr. Borish said.

In early clinical trials in people with asthma, the artificial IL-4 receptor has had no side effects, remained in the body for 8 days and kept allergy symptoms from occurring. In addition, the use of an inhaled IL-4 receptor reduced the use of other asthma medications, such as beta-agonists and inhaled corticosteroids.

The latest clinical trial using inhaled IL-4 receptors currently is accepting new patients. Patients will receive one dose of IL-4 every week for 12 weeks. Patients must live in the Denver metropolitan area. For information on enrolling in the study, call (303) 398-1911.

Artificial IL-4 receptors could be widely available as a treatment option in two to three years.

National Jewish researchers have done many of the preliminary studies on IL-4 showing that IL-4 is a major gene that causes allergies and that mice without IL-4 genes don't get asthma.


Story Source:

The above story is based on materials provided by National Jewish Medical And Research Center. Note: Materials may be edited for content and length.


Cite This Page:

National Jewish Medical And Research Center. "Artificial Il-4 Receptor Could Stop Allergies, Help People With Allergic Asthma." ScienceDaily. ScienceDaily, 11 May 1998. <www.sciencedaily.com/releases/1998/05/980508101131.htm>.
National Jewish Medical And Research Center. (1998, May 11). Artificial Il-4 Receptor Could Stop Allergies, Help People With Allergic Asthma. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1998/05/980508101131.htm
National Jewish Medical And Research Center. "Artificial Il-4 Receptor Could Stop Allergies, Help People With Allergic Asthma." ScienceDaily. www.sciencedaily.com/releases/1998/05/980508101131.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins